Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia
Status:
RECRUITING
Trial end date:
2029-11-01
Target enrollment:
Participant gender:
Summary
It is a non-randomized, multicenter, prospective study, aiming to treat patients with newly diagnosed acute promyelocytic leukemia with a combination of oral arsenic and atra, with low dose chemotherapy for those with high-risk disease (white blood cell count above 10x10a9/L). The primary objective is to assess the 2-year overall survival (OS) in these patients, comparing with the historical control group of patients treated with ATRA/chemotherapy according to the IC-APL 2006 protocol.